CO5261491A1 - Compuestos acetamida tiazolil sustituidos y aminosulfonil - Google Patents
Compuestos acetamida tiazolil sustituidos y aminosulfonilInfo
- Publication number
- CO5261491A1 CO5261491A1 CO00097414A CO00097414A CO5261491A1 CO 5261491 A1 CO5261491 A1 CO 5261491A1 CO 00097414 A CO00097414 A CO 00097414A CO 00097414 A CO00097414 A CO 00097414A CO 5261491 A1 CO5261491 A1 CO 5261491A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkoxy
- halogen
- substituted
- eventually
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 2
- 229910052736 halogen Inorganic materials 0.000 abstract 17
- 229910052757 nitrogen Inorganic materials 0.000 abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 14
- 150000002367 halogens Chemical group 0.000 abstract 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 9
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- -1 alkoxy- (C1-C6) Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical compound C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 abstract 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 abstract 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 abstract 2
- 125000006823 (C1-C6) acyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuestos de la fórmula general 1:<EMI FILE="00097414_1" ID="1" IMF=JPEG >En la cual R1 representa hidrógeno, halógeno, alquilo (C1-C6), alcoxi-(C1-C6), aminoalquilo (C1-C6), o halógenoalquilo (C1.C6), R2 y R3 son iguales o diferentes y representan hidrógeno, alcoxi (C1-C6), cicloalquilo (C3-C8),o bifenilaminocarbonilo, o representan alquilo (C1-C6), que eventualmente está sustituido con 1 a 3 sustituyentes que se seleccionan del grupo constituido por cicloalquilo (C1-C6), alcoxi (C1-C6), halogeno, hidroxi, amino, trialquil (C1-C6), sililoxi, restos de fórmulas <EMI FILE="00097414_2" ID="2" IMF=JPEG >en la que R2AND#39 es hidrógeno o alquilo (C1-C4), un heterociclo aromático de 5 a 6 elementos con hasta 3 heteroátomos de la serie S, N y/o O, pudiendo también estar a través de un átomo de nitrógeno un heterociclo con nitrógeno, un heterociclo no aromático, saturado o insaturado de 3 a 8 elementos, eventualmente unido a través de un átomo de nitrógeno, con hasta 3 heteroátomos de la serie S, N y/o O y arilo (C6-C10), que a su vez puede estar sustituido con hidroxi o alcoxi (C1-C6), orepresentan un grupo de fórmula <EMI FILE="00097414_3" ID="3" IMF=JPEG > - 2 -en la que R8 y R9 son iguales o diferentes entre sí y representan hidrógeno y alquilo (C1-C4), o representa un grupo de fórmula <EMI FILE="00097414_4" ID="4" IMF=JPEG > en la que R10 representa el grupo lateral de un a-aminoácido de origen natural, o representa un grupo de fórmula <EMI FILE="00097414_5" ID="5" IMF=JPEG > en la que R11 representa alquilo (C1-C4) y R12 representa hidrógeno, alquilo (C1-C4) o representa un grupo de fórmula <EMI FILE="00097414_6" ID="6" IMF=JPEG >en la R10 representa el grupo lateral de un a-aminoácido de origen natural, o R2 y R3 junto con el átomo de nitrógeno forman un heterociclo saturado de 5 a 6 elementos, que eventualmente puede contener otro átomo de oxígeno, R4 representa hidrógeno, acilo (C1-C6), alquenilo (C2.C6), cicloalquilo (C3-C8), o R4 representa alquilo (C1-C6), que eventualmente puede estar sustituido con 1 a 3 sustituyentes, que se seleccionan del grupo constituido por halógeno, hidroxi, cicloalquilo (C3-C6), acilo (C1-C6) alcoxi (C1-C6) carboxilo, <EMI FILE="00097414_7" ID="7" IMF=JPEG >en la que R4 representa hidrógeno, -(OCH2CH2)NOCH2CH3; en la que n es 0 ó 1, fenoxi, arilo (C6.-C10) y -NR13 R14, en la que R13 y R14 son iguales o diferentes y significan hidrógeno, acilo (C1-C6), alquilo (C1-C6), carbamoílo, mono o dialquilamino (C1-C6) alquilo (C1-C6), mono o dialquilamino (C1-C6) carbonilo, arilo (C6-C10) o alcoxi (C1-C6) carbonilo, o R13 y R14 junto con el átomo de nitrógeno forman un heterociclo saturado de 5 a 6 elementos, que eventualmente puede contener otro heteroátomo de la serie S u O o un resto de fórmula -NR15 y que puede estar sustituido con oxoen la que R15 significa hidrógeno o alquilo (C1-C4), o R4 representa con un heterociclo aromático, eventualmente benzocondensado, de 5 a 6 elementos, con hasta 3 heteroátomos de la serie S, N y/o O, pudiendo estar también unido un heterociclo con nitrógeno a través del átomo de nitrógeno, o estar sustituido con restos de fórmulas <EMI FILE="00097414_8" ID="8" IMF=JPEG >en las queR16 significa hidrógeno o alquilo (C1-C6),R17 y R18 son iguales o diferentes y significan hidrógeno, alquilo (C1-C6) o arilo (C6-C10), en los que los anteriormente citados alquilo (C1-C6) y arilo (C6-C10) pueden estar eventualmente sustituidos con 1 a 3 sustituyentes, seleccionados del grupo constituido por hidroxi, alcoxi (C1-C6) y halógeno,R5 representa hidrógeno, alquilo (C1-C6), halógeno, amino, mono o dialquilamino (C1-C6), o representa alcanoilamino (C1-C6),R6 representa fenilo, que eventualmente puede estar sustituido con uno a tres sustituyentes seleccionados del grupo constituido por- halógeno, - 3 -- Arilo (C6-C10) que eventualmente puede estar sustituido con 1 a 3 sustituyentes seleccionados entre alcanoílo (C1-C6), alcoxi (C1-C6) alquilo (C1-C6) halógeno, alcoxi (C1-C6) carbonilo, nitro, halógenoalquilo (C1-C6), halógenoalcoxi (C1-C6), amino, alquiltio (C1-C6), hidroxi, carboxilo, carbamoílo, mono o dialquilamino (C1-C6) carbonilo, mono o dialcanoilamino (C1-C6), alcoxi (C1-C6) carbonilamino, alquil (C1-C6) sulfoxi, alquil (C1-C6), sulfonilo, trialquil (C1-C6) sililoxi, un heterociclo mono o bicíclico, no aromático, saturado o insaturado, con 3 a 8 elementos y eventualmente unido a través de un átomo de nitrógeno, con hasta 3 heteroátomos de la serie S, N y/o O, y/o ciano,- Alcoxi (C1-C6),- Alcoxi (C1-C6) carbonilo,- Alquiltío (C1-C6),- Hidroxi,- Carboxilo,- Alcoxi (C1-C6) parcialmente fluorado con hasta 6 átomos de flúor,Alquilo (C1-C6), que eventualmente está sustituido con un resto de fórmula<EMI FILE="00097414_9" ID="9" IMF=JPEG >- Un heterociclo aromático con 5 a 6 elementos, eventualmente unido a través de un átomo de nitrógeno, con hasta 3 heteroátomos de la serie S, N y/o O, que eventualmente puede estar sustituido con 1 a 3 sustituyentes, seleccionados entre alcanoílo (C1-C6) alcoxi (C1-C6), alquilo (C1-C6), halógeno, alcoxi (C1-C6) carbonilo, nitro, halógenoalquilo (C1-C6), halógenoalcoxi (C1-C6), amino, alquiltío (C1-C6), hidroxi, carboxilo, carbamoílo, aminocarbonilo, mono o dialquilamino (C1-C6) carbonilo, mono o dialcanoilamino (C1-C6), alcoxi (C1-C6) carbonilamino, alquil (C1-C6) sulfoxi, alquil (C1-C6) sulfonilo, un heterociclo mono o bicíclico, no aromático, saturado o insaturado, con 3 a 8 elementos y eventualmente unido a través de un átomo de nitrógeno, con hasta 3 heteroátomos de la serie S, N y/o O, y/o ciano,Un heterociclo mono o bicíclico, no aromático, saturado o insaturado, con 3 a 8 elementos eventualmente unido a través de un átomo de nitrógeno, con hasta 3 heteroátomos de la serie S, N y/o O, que eventualmente puede estar sustituido con 1 a 3 sustituyentes seleccionados entre oxo, halógeno, hidroxi, alcoxi (C1-C6) carbonilo, alcoxi (C1-C6) carbonilo, alcoxi (C1-C6) carbonilamino, alquilo (C1-C6), halógenoalquilo (C1-C6) e hidroxialquilo (C1-C6),- Alquenilo (C1-C6)- grupos de fórmulas- OR19,- OR20R21 o -CO - NR22R23,- Carbazol, dibenzofurano o dibenzotiofeno,- xanteno o 9,10-dihidroacridina,en las que R19 significa fenilo, que a su vez está sustituido eventualmente con un grupo de fórmula -NR2R25,en la queR24 y R25 son iguales o diferentes y representan hidrógeno, alquilo (C1-C6) o acilo (C1-C6),oR19 significa alquilo (C1-C6), que eventualmente está sustituido de una a tres veces con hidroxi y/o halógeno,R20 y R21 son iguales o diferentes y representan hidrógeno, carbamoílo, mono o dialquilamino (C1-C6) carbonilo, fenilo, acilo (C1-C6) o alquilo (C1-C6),estando el alquilo (C1-C6) anteriormente citado eventualmente sustituido con alcoxi (C1-C6), acilo (C1-C6), fenilo o con un heterociclo aromático de 5 a 6 elementos con hasta 3 heteroátomos de la serie S, N, y/o O,estando el fenilo anteriormente citado y el heterociclo aromático anteriormente citado eventualmente sustituido de una a tres veces, de forma igual o distinta, con halógeno y/o hidroxi, yR22 y R23 son iguales o diferentes y significan hidrógeno o alquilo (C1-C6),y R7 puede tener el significado de R5, pudiendo ser igual o diferente a aquel,y sus sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19962532A DE19962532A1 (de) | 1999-12-23 | 1999-12-23 | Thiazolylamid-Derivate |
| DE10039265A DE10039265A1 (de) | 2000-08-11 | 2000-08-11 | Thiazolylamid-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5261491A1 true CO5261491A1 (es) | 2003-03-31 |
Family
ID=26006669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00097414A CO5261491A1 (es) | 1999-12-23 | 2000-12-22 | Compuestos acetamida tiazolil sustituidos y aminosulfonil |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7105553B2 (es) |
| EP (1) | EP1244641B1 (es) |
| JP (1) | JP4726175B2 (es) |
| KR (1) | KR100768361B1 (es) |
| CN (1) | CN1235890C (es) |
| AR (1) | AR029210A1 (es) |
| AT (1) | ATE293104T1 (es) |
| AU (1) | AU784286B2 (es) |
| BR (1) | BR0017030B8 (es) |
| CA (1) | CA2396720C (es) |
| CO (1) | CO5261491A1 (es) |
| DE (1) | DE50010060D1 (es) |
| DK (1) | DK1244641T3 (es) |
| DO (1) | DOP2000000109A (es) |
| ES (1) | ES2240233T3 (es) |
| HK (1) | HK1057552A1 (es) |
| IL (2) | IL149897A0 (es) |
| MX (1) | MXPA02006243A (es) |
| MY (1) | MY134880A (es) |
| NZ (1) | NZ519701A (es) |
| PE (1) | PE20010964A1 (es) |
| PL (1) | PL208707B1 (es) |
| PT (1) | PT1244641E (es) |
| SV (1) | SV2002000249A (es) |
| TW (1) | TWI256951B (es) |
| UY (1) | UY26495A1 (es) |
| WO (1) | WO2001047904A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000259734A1 (en) * | 2000-06-15 | 2001-12-24 | Gerald Kleymann | Method for identifying compounds with anti-herpes activity |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| EP2179744B1 (en) * | 2004-09-09 | 2010-12-01 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential latrogenic risks associated with influenza vaccines |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| AU2006343359A1 (en) * | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20070032488A1 (en) * | 2005-08-05 | 2007-02-08 | Genelabs Technologies, Inc. | 6-Membered aryl and heteroaryl derivatives for treating viruses |
| CA2620878A1 (en) * | 2005-08-29 | 2007-04-05 | Gerard M. Housey | Theramutein modulators |
| MX368352B (es) * | 2006-03-17 | 2019-09-30 | Univ Johns Hopkins | Derivados de n-hidroxilsulfonamida como nuevos donantes de nitroxilo fisiologicamente utiles. |
| US20100051879A1 (en) * | 2006-11-22 | 2010-03-04 | The Regents od the Univesity of California | Functionalized Boron Nitride Nanotubes |
| EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| JP2016507546A (ja) * | 2013-02-12 | 2016-03-10 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | アルツハイマー病を治療する方法において使用するためのヘリカーゼ／プライマーゼ阻害剤 |
| WO2016007538A1 (en) * | 2014-07-07 | 2016-01-14 | Prophylaxis, Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| MY198018A (en) * | 2016-04-06 | 2023-07-26 | Lnnovative Molecules Gmbh | Aminothiazole derivatives useful as antiviral agents |
| DK3544976T3 (da) * | 2016-11-28 | 2021-05-10 | Aicuris Gmbh & Co Kg | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf |
| HUE054845T2 (hu) * | 2016-11-28 | 2021-10-28 | Aicuris Gmbh & Co Kg | Az N-[5-(amino-szulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamid szabad bázis maleát sója, gyógyászati készítmények, elõállítási eljárások és Herpes vírusok kezelésére történõ alkalmazások |
| WO2018095576A1 (en) | 2016-11-28 | 2018-05-31 | Aicuris Anti-Infective Cures Gmbh | Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide |
| EP3566749A4 (en) * | 2017-01-09 | 2020-09-23 | Medshine Discovery Inc. | THIAZOLE DERIVATIVE AND USES OF IT |
| SI3692039T1 (sl) | 2017-10-05 | 2023-04-28 | Innovative Molecules Gmbh | Enantomeri substituiranih tiazolov kot protivirusne spojine |
| AU2019297214B2 (en) * | 2018-07-06 | 2022-07-07 | Phaeno Therapeutics Co., Ltd. | Crystal forms of thiazole compound and application thereof |
| EP3925595A1 (en) | 2020-06-17 | 2021-12-22 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate |
| KR20220160024A (ko) | 2020-03-26 | 2022-12-05 | 아이쿠리스 게엠베하 운트 코. 카게 | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 반수화물을 포함하는 안과용 제제 |
| MX2023004955A (es) | 2020-10-29 | 2023-05-17 | Innovative Molecules Gmbh | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
| TW202337444A (zh) | 2022-01-17 | 2023-10-01 | 德商創新分子有限責任公司 | 解旋酶引子酶抑制劑的固體結晶形式及其製備方法 |
| WO2024047506A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| WO2024047507A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| WO2024047508A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions for herpes virus |
| WO2024049760A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3658830A (en) | 1970-01-16 | 1972-04-25 | Shell Oil Co | 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl) |
| CA984848A (en) | 1970-01-16 | 1976-03-02 | Kurt H. Pilgram | Herbicides |
| US3847588A (en) | 1970-04-20 | 1974-11-12 | Shell Oil Co | Thiazoles herbicidal |
| US3717651A (en) | 1970-04-20 | 1973-02-20 | Shell Oil Co | Thiazoles |
| WO1997024343A1 (en) | 1995-12-29 | 1997-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenyl thiazole derivatives with anti herpes virus properties |
| GB2311068A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Helicase isolated from human cytomegalovirus (HCMV) |
| GB2311069A (en) | 1996-03-14 | 1997-09-17 | Merck & Co Inc | Primase isolated from human cytomegalovirus (HCMV) |
| US5705344A (en) | 1996-03-14 | 1998-01-06 | Tularik, Inc. | High-throughput screening assay for inhibitors of nucleic acid helicases |
| CA2223032A1 (en) | 1997-02-21 | 1998-08-21 | Smithkline Beecham Corporation | Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents |
| DE19802437A1 (de) | 1998-01-23 | 1999-07-29 | Bayer Ag | Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| AU743489B2 (en) | 1998-03-19 | 2002-01-24 | Pharmacia & Upjohn Company | 1,3,4-thiadiazoles useful for the treatment of CMV infections |
| AU2914200A (en) | 1999-03-08 | 2000-09-28 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
-
2000
- 2000-12-05 DO DO2000000109A patent/DOP2000000109A/es unknown
- 2000-12-12 KR KR1020027008155A patent/KR100768361B1/ko active IP Right Grant
- 2000-12-12 CA CA002396720A patent/CA2396720C/en not_active Expired - Lifetime
- 2000-12-12 WO PCT/EP2000/012564 patent/WO2001047904A1/de active IP Right Grant
- 2000-12-12 PT PT00991169T patent/PT1244641E/pt unknown
- 2000-12-12 DK DK00991169T patent/DK1244641T3/da active
- 2000-12-12 NZ NZ519701A patent/NZ519701A/en not_active IP Right Cessation
- 2000-12-12 AU AU31574/01A patent/AU784286B2/en not_active Expired
- 2000-12-12 PL PL356484A patent/PL208707B1/pl unknown
- 2000-12-12 AT AT00991169T patent/ATE293104T1/de active
- 2000-12-12 DE DE50010060T patent/DE50010060D1/de not_active Expired - Lifetime
- 2000-12-12 BR BRPI0017030A patent/BR0017030B8/pt not_active IP Right Cessation
- 2000-12-12 CN CNB008189676A patent/CN1235890C/zh not_active Expired - Lifetime
- 2000-12-12 US US10/168,197 patent/US7105553B2/en not_active Expired - Lifetime
- 2000-12-12 IL IL14989700A patent/IL149897A0/xx active IP Right Grant
- 2000-12-12 EP EP00991169A patent/EP1244641B1/de not_active Expired - Lifetime
- 2000-12-12 ES ES00991169T patent/ES2240233T3/es not_active Expired - Lifetime
- 2000-12-12 MX MXPA02006243A patent/MXPA02006243A/es active IP Right Grant
- 2000-12-12 JP JP2001549375A patent/JP4726175B2/ja not_active Expired - Lifetime
- 2000-12-20 AR ARP000106789A patent/AR029210A1/es active IP Right Grant
- 2000-12-20 UY UY26495A patent/UY26495A1/es not_active Application Discontinuation
- 2000-12-21 MY MYPI20006089A patent/MY134880A/en unknown
- 2000-12-22 TW TW089127599A patent/TWI256951B/zh not_active IP Right Cessation
- 2000-12-22 CO CO00097414A patent/CO5261491A1/es active IP Right Grant
- 2000-12-22 SV SV2000000249A patent/SV2002000249A/es active IP Right Grant
- 2000-12-22 PE PE2000001387A patent/PE20010964A1/es not_active IP Right Cessation
-
2002
- 2002-05-28 IL IL149897A patent/IL149897A/en unknown
-
2004
- 2004-01-19 HK HK04100401A patent/HK1057552A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261491A1 (es) | Compuestos acetamida tiazolil sustituidos y aminosulfonil | |
| AR009212A1 (es) | Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen | |
| CO5550472A2 (es) | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| CO5021127A1 (es) | Nuevas dihidropirimidas | |
| CO5170444A1 (es) | Pirazolobenzodiazepinas | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| AR044796A1 (es) | Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv | |
| AR044795A1 (es) | Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv | |
| PE20020756A1 (es) | Imidazotriazinonas sustituidas como inhibidores de la fosfodiesterasa pde 2 | |
| CO5271649A1 (es) | Pirazolopirimidinonas inhibidoras de gmp[sub c] pde5 para el tratamiento de la disfuncion sexual | |
| ES2191484T3 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
| PE20010042A1 (es) | Ent-esteroides en calidad de estrogenos con efecto selectivo | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| ECSP088149A (es) | 3-acilaminobenzanilidas insecticidas | |
| ES2193990T3 (es) | Derivados de purina. | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| AR076896A2 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados | |
| AR017729A1 (es) | Composicion y procedimientos para el tenido de las fibras queratinicas y en particular de las fibras queratinicas humanas tales como los cabellos y un dispositivo de varios compartimientos o kit de tenido de varios compartimientos. | |
| CY1105554T1 (el) | Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης | |
| ES2253568T3 (es) | Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias. | |
| CO5601006A2 (es) | Procedimiento para la preparacion de esteres de escopina | |
| AR039385A1 (es) | Derivados de tioxantina como inhibidores de la mieloperoxidasa | |
| CO5590924A2 (es) | Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6 | |
| TW200508359A (en) | Quinoxaline derivatives, and light emitting element using thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |